Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy agent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    899 result(s) found for: Chemotherapy agent. Displaying page 7 of 45.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2005-005612-24 Sponsor Protocol Number: EMMA-1 Start Date*: 2006-06-29
    Sponsor Name:University of Cologne
    Full Title: PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA EMMA-1 (ERBITUX FOR MULTIPLE MYELOMA)
    Medical condition: Relapsed or refractory multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001509-25 Sponsor Protocol Number: RHMCAN0860 Start Date*: 2012-09-25
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial A randomised, Phase II, double-blind, placebo-controlled, two arm Trial to establish whether Aspirin can reduce hearing loss/ototoxicity fo...
    Medical condition: To establish whether Aspirin can reduce hearing loss/ototoxicity for patients receiving Cisplatin based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10013993 - Ear and labyrinth disorders 10033109 Ototoxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001088-29 Sponsor Protocol Number: CJDQ443B12201 Start Date*: 2022-10-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-sm...
    Medical condition: locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) BG (Completed) NL (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004333-34 Sponsor Protocol Number: EORTC 55041 Start Date*: 2005-09-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I an...
    Medical condition: Histologically confirmed high-risk FIGO stage I (grade 3, or aneuploid grade 1 or 2, or clear cell), or Stages II-IV ovarian epithelial, primary peritoneal, and fallopian tube cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10033283 HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001496-20 Sponsor Protocol Number: ISRCTN43372330 Start Date*: 2008-06-06
    Sponsor Name:University College London
    Full Title: Breakthrough Breast Cancer & Cancer Research UK Genetic Breast Cancer Trial: A randomised phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast can...
    Medical condition: Metastatic breast cancer in women with BRCA1 or BRCA 2 mutation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed) SE (Ongoing) ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002905-34 Sponsor Protocol Number: PP 01-07 Start Date*: 2008-03-19
    Sponsor Name:PledPharma AB
    Full Title: A LOCAL FEASIBILITY STUDY ON MANGAFODIPIR AS AN ADJUNCT TO FOLFOX6 CHEMOTHERAPY IN PATIENTS OPERATED FOR COLORECTAL CANCER STAGE DUKE C (MANFOL)
    Medical condition: The study subjects will be patients with operated colorectal cancer stage Duke C who are going through standard FOLFOX6 treatment (5-FU, calcium-levofoliate and oxaliplatin). The objective of the s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014491-21 Sponsor Protocol Number: Start Date*: 2009-12-17
    Sponsor Name:Cambridge University Hospitals NHS Trust
    Full Title: Neoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy.
    Medical condition: Neoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000618-39 Sponsor Protocol Number: Sym004-13 Start Date*: 2018-10-23
    Sponsor Name:Symphogen A/S
    Full Title: A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Met...
    Medical condition: Metastatic Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000524-16 Sponsor Protocol Number: A6181054 Start Date*: 2006-01-12
    Sponsor Name:Laboratorios Pfizer, Lda
    Full Title: AN OPEN LABEL INTERNATIONAL MULTI-CENTER PHASE 2 ACTIVITY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH ADVANCED / METASTATIC GASTRIC CANCER PROGRESSING OR RECURRING AFTER ONE PRIOR CHEMOTHERAPY
    Medical condition: Histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (i.e. an adenocarcinoma with >50% extension in the stomach). Patients must...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10017758 LLY
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006330-16 Sponsor Protocol Number: IRFMN-MPM-6077 Start Date*: 2013-05-23
    Sponsor Name:Istituto di ricerche farmacologiche "Mario Negri"
    Full Title: ATREUS TRIAL A PHASE II STUDY ON THE ACTIVITY OF TRABECTEDIN IN PRETREATED EPITHELIOID OR BIPHASIC/SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Medical condition: Malignant Pleural Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003822-25 Sponsor Protocol Number: EORTC 08051 Start Date*: 2006-06-19
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized Phase II Study Of Pemetrexed And Cisplatin As Either Induction or Adjuvant Chemotherapy In Stage IB-II Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: Stage IB-II Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029518 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005210-20 Sponsor Protocol Number: 2005-005210-20 Start Date*: 2006-04-10
    Sponsor Name:CHU Sart-Tilman
    Full Title: Phase II trial of caspofungin as secondary prophylaxis for invasive fungal infections in patients with high-risk hematological malignancies undergoing intensive chemotherapy or hematopoietic stem ...
    Medical condition: Acute leukemia during induction or consolidation therapy. Autologous HSCT for a hematological malignancy. Standard allogeneic HSCT with a myeloablative conditioning regimen.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002784-10 Sponsor Protocol Number: CESM Start Date*: 2012-07-12
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: Clinical trial comparing contrast enhanced spectral digital mammography (CESM) and magnetic resonance imaging (MRI) to evaluate the effectiveness of neoadjuvant chemotherapy in patients with locall...
    Medical condition: patient with cito-istologic diagnosis of locally advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000370-10 Sponsor Protocol Number: POLEMCCR4673 Start Date*: 2018-05-09
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomised study.
    Medical condition: Colon cancer stage III
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009949 Colon cancer Duke's C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-001930-93 Sponsor Protocol Number: GC-627-04 Start Date*: 2017-01-13
    Sponsor Name:Generon (Shanghai) Corporation Ltd.
    Full Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
    Medical condition: Women, between 18 and 75 years of age that have been diagnosed with Stage II-IV breast cancer in the adjuvant or metastatic setting and are scheduled to undergo chemotherapy. This is a profilaxis ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-000544-86 Sponsor Protocol Number: 11848 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG; D-51368 Leverkusen
    Full Title: A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or me...
    Medical condition: unresectable and/or metastatic renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000137-37 Sponsor Protocol Number: PALO-03-13 Start Date*: 2005-09-23
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Palonosetron 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Palonosetron 0.25 mg IV for the Preventio...
    Medical condition: Moderately emetogenic chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-004910-33 Sponsor Protocol Number: PAZOTEST-01 Start Date*: 2012-12-24
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of single-agent Pazopanib (Votrient) for patients with relapsed or refractory germ-cell tumors (GCT).
    Medical condition: Testicular or extragonadal germ cell tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10018187 Genitourinary neoplasms malignancy and gender unspecified HLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000266-64 Sponsor Protocol Number: PEGF/USV/P3/003 Start Date*: 2015-06-18
    Sponsor Name:USV Limited
    Full Title: A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer Pa...
    Medical condition: Duration of Sever Neutropenia and incidence of febrile neutropenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    18.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-001555-19 Sponsor Protocol Number: HE 2D07 Start Date*: 2008-02-26
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: DOCETAXEL COMBINED WITH PULSATILE ERLOTINIB (TARCEVA) IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
    Medical condition: Metastatic (stage IV) non-small cell lung cancer (NSCLC) who have not previously been treated with anticancer drugs
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 07:27:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA